| 11. |
- Dimov, Stefan S., et al.
(författare)
-
4M Network of Excellence, Progress Report 2006-2008
- 2008
-
Ingår i: 4M 2008. - Dunbeath : Whittles Publishing. - 9781904445760 ; , s. xv-xxxi
-
Konferensbidrag (refereegranskat)abstract
- This report follows on from last year's "Progress Report 2004-2006" and gives an update on the continuing activities, such as the 4M Network cross-divisional projects and annual conference, as well as a description of the new activities in its third and forth year, such as the first 4M Summer School and Book Series. Finally, as the end of the funded lifetime of the network approaches the steps being taken to set up a 4M Association, which aims to create the organizational infrastructure to support the 4M Knowledge Community established in the last five years, are described.
|
|
| 12. |
- Dimov, Stefan S., et al.
(författare)
-
4M Network of Excellence, Progress report 2009
- 2009
-
Ingår i: 4M/ICOMM 2009. ; , s. s.1-9
-
Konferensbidrag (refereegranskat)abstract
- This paper gives a brief overview of the activities of the 4M Network of Excellence during the last nine months of its funded period. The 4M Divisions summarise their activity and outline their plans to continue to working together in future. Finally a summary of achievements during the whole lifetime of the Network is given
|
|
| 13. |
- Ferrannini, E., et al.
(författare)
-
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
- 2009
-
Ingår i: Diabetes, Obesity and Metabolism. - : Wiley. - 1462-8902 .- 1463-1326. ; 11:2, s. 157-166
-
Tidskriftsartikel (refereegranskat)abstract
- To examine the efficacy and safety of vildagliptin vs. glimepiride as add-on therapy to metformin in patients with type 2 diabetes mellitus in a 52-week interim analysis of a large, randomized, double-blind, multicentre study. The primary objective was to demonstrate non-inferiority of vildagliptin vs. glimepiride in glycosylated haemoglobin (HbA(1c)) reduction at week 52. Patients inadequately controlled on metformin monotherapy (HbA(1c) 6.5-8.5%) and receiving a stable dose of metformin (mean dose 1898 mg/day; mean duration of use 36 months) were randomized 1:1 to receive vildagliptin (50 mg twice daily, n = 1396) or glimepiride (titrated up to 6 mg/day; mean dose 4.5 mg/day, n = 1393). Non-inferiority of vildagliptin was demonstrated (97.5% confidence interval 0.02%, 0.16%) with a mean (SE) change from baseline HbA(1c) (7.3% in both groups) to week 52 endpoint of -0.44% (0.02%) with vildagliptin and -0.53% (0.02%) with glimepiride. Although a similar proportion of patients reached a target HbA(1c) level of < 7% with vildagliptin and glimepiride (54.1 and 55.5%, respectively), a greater proportion of patients reached this target without hypoglycaemia in the vildagliptin group (50.9 vs. 44.3%; p < 0.01). Fasting plasma glucose (FPG) reductions were comparable between groups (mean [SE] -1.01 [0.06] mmol/l and -1.14 [0.06] mmol/l respectively). Vildagliptin significantly reduced body weight relative to glimepiride (mean [SE] change from baseline -0.23 [0.11] kg; between-group difference -1.79 kg; p < 0.001) and resulted in a 10-fold lower incidence of hypoglycaemia than glimepiride (1.7 vs. 16.2% of patients presenting at least one hypoglycaemic event; 39 vs. 554 hypoglycaemic events, p < 0.01). No severe hypoglycaemia occurred with vildagliptin compared with 10 episodes with glimepiride (p < 0.01), and no patient in the vildagliptin group discontinued because of hypoglycaemia compared with 11 patients in the glimepiride group. The incidence of adverse events (AEs), serious AEs and adjudicated cardiovascular events was 74.5, 7.1 and 0.9%, respectively, in patients receiving vildagliptin, and 81.1, 9.5 and 1.6%, respectively, in patients receiving glimepiride. When metformin alone fails to maintain sufficient glycaemic control, the addition of vildagliptin provides comparable efficacy to that of glimepiride after 52 weeks and displays a favourable AE profile, with no weight gain and a significant reduction in hypoglycaemia compared with glimepiride.
|
|
| 14. |
- Gaffney, K J, et al.
(författare)
-
Observation of structural anisotropy and the onset of liquidlike motion during the nonthermal melting of InSb
- 2005
-
Ingår i: Physical Review Letters. - : American Physical Society. - 0031-9007 .- 1079-7114. ; 95:12
-
Tidskriftsartikel (refereegranskat)abstract
- The melting dynamics of laser excited InSb have been studied with femtosecond x-ray diffraction. These measurements observe the delayed onset of diffusive atomic motion, signaling the appearance of liquidlike dynamics. They also demonstrate that the root-mean-squared displacement in the [111] direction increases faster than in the [110] direction after the first 500 fs. This structural anisotropy indicates that the initially generated fluid differs significantly from the equilibrium liquid.
|
|
| 15. |
- Hareter, M., et al.
(författare)
-
MOST discovers a multimode delta Scuti star in a triple system : HD 61199
- 2008
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 492:1, s. 185-195
-
Tidskriftsartikel (refereegranskat)abstract
- Context. A field star, HD61199 (V approximate to 8), simultaneously observed with Procyon by the MOST (Microvariability & Oscillations of STars) satellite in continuous runs of 34, 17, and 34 days in 2004, 2005, and 2007, was found to pulsate in 11 frequencies in the delta Scuti range with amplitudes from 1.7 down to 0.09 mmag. The photometry also showed variations with a period of about four days. To investigate the nature of the longer period, 45 days of time-resolved spectroscopy was obtained at the Thuringer Landessternwarte Tautenburg in 2004. The radial velocity measurements indicate that HD61199 is a triple system. Aims. A delta Scuti pulsator with a rich eigenspectrum in a multiple system is promising for asteroseismology. Our objectives were to identify which of the stars in the system is the delta Scuti variable and to obtain the orbital elements of the system and the fundamental parameters of the individual components, which are constrained by the pulsation frequencies of the delta Scuti star.Methods. Classical Fourier techniques and least-squares multi-sinusoidal fits were applied to the MOST photometry to identify the pulsation frequencies. The groundbased spectroscopy was analysed with least-squares-deconvolution (LSD) techniques, and the orbital elements derived with the KOREL and ORBITX routines. Asteroseismic models were also generated. Results. The photometric and spectroscopic data are compatible with a triple system consisting of a close binary with an orbital period of 3.57 days and a d Scuti companion (HD61199 A) as the most luminous component. The d Scuti star is a rapid rotator with about v sin i = 130 km s(-1) and an upper mass limit of about 2.1 M-circle dot. For the close binary components, we find they are of nearly equal mass, with lower mass limits of about 0.7 M-circle dot. Comparisons to synthetic spectra indicate these stars have a late-F spectral type. The observed oscillation frequencies are compared to pulsation models to further constrain the evolutionary state and mass of HD61199 A. The orbit frequency of the close binary corresponds to the difference of the two d Scuti frequencies with the highest amplitudes a coincidence that is remarkable, but not explained.
|
|
| 16. |
- Hirai, T., et al.
(författare)
-
R&D on full tungsten divertor and beryllium wall for JET ITER-like wall project
- 2007
-
Ingår i: Fusion engineering and design. - : Elsevier BV. - 0920-3796 .- 1873-7196. ; 82:15-24, s. 1839-1845
-
Tidskriftsartikel (refereegranskat)abstract
- The ITER reference materials have been tested separately in tokamaks, plasma simulators, ion beams and high heat flux test beds. In order to perform a fully integrated material test JET has launched the ITER-like Wall Project with the aim of installing a full metal wall during the next major shutdown. As a result of R&D projects in 2005-2006, bulk tungsten tiles are foreseen at the outer horizontal target and tungsten coating at the other divertor tiles. In some regions of the main chamber, beryllium coated Inconel tiles and bulk beryllium tiles are utilised which include marker tiles as erosion diagnostics. This paper gives an overview of the R&D carried out in the frame of the ITER-like Wall Project on the development of an inertially cooled bulk tungsten tile design and the characterization of tungsten and beryllium coating technologies.
|
|
| 17. |
|
|
| 18. |
- Jendle, Johan, et al.
(författare)
-
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
- 2009
-
Ingår i: Diabetes, obesity and metabolism. - : Wiley. - 1462-8902 .- 1463-1326. ; 11:12, s. 1163-1172
-
Tidskriftsartikel (refereegranskat)abstract
- Aim The effect on body composition of liraglutide, a once-daily human glucagon-like peptide-1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D). Methods These were randomized, double-blind, parallel-group trials of 26 [Liraglutide Effect and Action in Diabetes-2 (LEAD-2)] and 52 weeks (LEAD-3). Patients with T2D, aged 18-80 years, body mass index (BMI) < 40 kg/m2 (LEAD-2), < 45 kg/m2 (LEAD-3) and HbA1c 7.0-11.0% were included. Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5-2 g/day in LEAD-2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD-3. LEAD-2/3: total lean body tissue, fat tissue and fat percentage were measured. LEAD-2: adipose tissue area and hepatic steatosis were assessed. Results LEAD-2: fat percentage with liraglutide 1.2 and 1.8 mg/metformin was significantly reduced vs. glimepiride/metformin (p < 0.05) but not vs. placebo. Visceral and subcutaneous adipose tissue areas were reduced from baseline in all liraglutide/metformin arms. Except with liraglutide 0.6 mg/metformin, reductions were significantly different vs. changes seen with glimepiride (p < 0.05) but not with placebo. Liver-to-spleen attenuation ratio increased with liraglutide 1.8 mg/metformin possibly indicating reduced hepatic steatosis. LEAD-3: reductions in fat mass and fat percentage with liraglutide monotherapy were significantly different vs. increases with glimepiride (p < 0.01). Conclusion Liraglutide (monotherapy or added to metformin) significantly reduced fat mass and fat percentage vs. glimepiride in patients with T2D.
|
|
| 19. |
- Maier, H., et al.
(författare)
-
Tungsten and beryllium armour development for the JET ITER-like wall project
- 2007
-
Ingår i: Nuclear Fusion. - : IOP Publishing. - 0029-5515 .- 1741-4326. ; 47:3, s. 222-227
-
Tidskriftsartikel (refereegranskat)abstract
- For the ITER-like wall project at JET the present main chamber CFC tiles will be exchanged with Be tiles and in parallel a fully tungsten-clad divertor will be prepared. Therefore three R&D programmes were initiated: Be coatings on Inconel as well as Be erosion markers were developed for the first wall of the main chamber. High heat flux screening and cyclic loading tests carried out on the Be coatings on Inconel showed excellent performance, above the required power and energy density. For the divertor a conceptual design for a bulk W horizontal target plate was investigated, with the emphasis on minimizing electromagnetic forces. The design consisted of stacks of W lamellae of 6 mm width that were insulated in the toroidal direction. High heat flux tests of a test module were performed with an electron beam at an absorbed power density Up to 9 MW m(-2) for more than 150 pulses and finally with increasing power loads leading to surface temperatures in excess of 3000 degrees C. No macroscopic failure occurred during the test while SEM showed the development of micro-cracks on the loaded surface. For all other divertor parts R&D was performed to provide the technology to coat the 2-directional CFC material used at JET with thin tungsten coatings. The W-coated CFC tiles were subjected to heat loads with power densities ranging up to 23.5 MW m(-2) and exposed to cyclic heat loading for 200 pulses at 10.5 MW m(-2). All coatings developed cracks perpendicular to the CFC fibres due to the stronger contraction of the coating upon cool-down after the heat pulses.
|
|
| 20. |
|
|
